Based on the key indicators related to LAVA Therapeutics' liquidity, profitability, solvency, and operating efficiency, LAVA Therapeutics NV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, LAVA Therapeutics' Other Current Liabilities is fairly stable compared to the past year. Total Stockholder Equity is likely to rise to about 63.1 M in 2024, whereas Total Assets are likely to drop slightly above 96.1 M in 2024. Key indicators impacting LAVA Therapeutics' financial strength include:
The financial analysis of LAVA Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize LAVA Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(44.07 Million)
LAVA
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Operating Cash Flow Sales Ratio
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Price Fair Value
Return On Equity
Investments
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Long Term Debt
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Short Term Debt
Property Plant Equipment
Other Liab
Tax Provision
Net Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Gross Profit
Probability Of Bankruptcy
Understanding current and past LAVA Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of LAVA Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in LAVA Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in LAVA Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of LAVA Therapeutics NV. Check LAVA Therapeutics' Beneish M Score to see the likelihood of LAVA Therapeutics' management manipulating its earnings.
LAVA Therapeutics Stock Summary
LAVA Therapeutics competes with Anebulo Pharmaceuticals, Pmv Pharmaceuticals, Bionomics, Edgewise Therapeutics, and Ikena Oncology. LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. Lava Therapeutics is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining LAVA Therapeutics's current stock value. Our valuation model uses many indicators to compare LAVA Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across LAVA Therapeutics competition to find correlations between indicators driving LAVA Therapeutics's intrinsic value. More Info.
LAVA Therapeutics NV is rated below average in return on equity category among its peers. It is rated third overall in return on asset category among its peers . At this time, LAVA Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the LAVA Therapeutics' earnings, one of the primary drivers of an investment's value.
LAVA Therapeutics Systematic Risk
LAVA Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. LAVA Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on LAVA Therapeutics correlated with the market. If Beta is less than 0 LAVA Therapeutics generally moves in the opposite direction as compared to the market. If LAVA Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one LAVA Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of LAVA Therapeutics is generally in the same direction as the market. If Beta > 1 LAVA Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in LAVA Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various LAVA Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of LAVA Therapeutics growth as a starting point in their analysis.
LAVA Therapeutics November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of LAVA Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of LAVA Therapeutics NV. We use our internally-developed statistical techniques to arrive at the intrinsic value of LAVA Therapeutics NV based on widely used predictive technical indicators. In general, we focus on analyzing LAVA Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build LAVA Therapeutics's daily price indicators and compare them against related drivers.
When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.